Related Experiment Video
Updated: Sep 3, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Correction: A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries
Hui-Hui Liu1, Sha Li2, Jian-Jun Li2
1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Heart Failure Center, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract:
[This corrects the article DOI: 10.3389/fphar.2026.1800502.].
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cardiovascular Drugs: Classification based on Therapeutic Indications
Atherosclerosis III: Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures